The sharp improvement in profitability metrics and sustained revenue growth suggest CARVYKTI® is scaling effectively. Traders should monitor whether the company can maintain this trajectory into 2026 and achieve company-wide operating profit as guided. The strong cash position supports continued R&D investment and potential pipeline acceleration.
Price Chart
Executive Summary
Legend Biotech reported strong Q4 and full-year 2025 financial results driven by CARVYKTI® sales, with $555 million in net trade sales for the quarter and $1.9 billion for the year. Total revenue reached $306.3 million in Q4, up 64% YoY, while adjusted net income turned positive at $2.5 million, a significant improvement from a $59.0 million loss in the prior year. The company achieved franchise profitability and maintained a robust cash position of $949 million.
Key Financial Metrics
Key Facts
- CARVYKTI® generated $555 million in net trade sales in Q4 2025 and $1.9 billion for the full year
- Total revenue was $306.3 million in Q4 2025, up 64% from $186.5 million in Q4 2024
- Adjusted net income was $2.5 million ($0.01 per share) in Q4 2025 vs. $59.0 million loss in Q4 2024
- Operating loss narrowed to $19.7 million from $79.3 million in the prior year
- Cash and cash equivalents plus time deposits totaled $949 million as of December 31, 2025
- Achieved CARVYKTI® franchise profitability for full-year 2025
- Over 10,000 patients treated globally with CARVYKTI®
Financial Impact
Revenue grew by $119.8 million QoQ and $1,028.9 million annually, with significant margin expansion and improved cash flow from operations
Risk Factors
- Net loss widened to $30.9 million in Q4 due to unrealized foreign exchange losses, highlighting currency risk exposure
- Dependency on Janssen collaboration for commercialization and revenue generation
- Forward-looking statements about achieving company-wide profitability in 2026 are uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252614 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 6-K | $19.80 | awaiting T+20 | — | $20.39 (+2.98%) |
Oct 13, 2026 13d ago | 6-K | $17.88 | awaiting T+20 | — | $20.39 (+14.04%) |
Sep 29, 2026 27d ago | 144 | $18.82 | awaiting T+20 | — | $20.39 (+8.34%) |
Sep 25, 2026 4w ago | 6-K | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.39 (+6.70%) |
Sep 25, 2026 4w ago | Press Release | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.39 (+6.70%) |
Sep 15, 2026 5w ago | 6-K | $17.67 $17.88 | ▲ +1.19% | ▼ −1.53% | $20.39 (+15.39%) |
Sep 14, 2026 6w ago | 6-K | $18.53 $17.80 | ▼ −3.94% | ▼ −6.20% | $20.39 (+10.04%) |
Aug 11, 2026 10w ago | 6-K | $21.83 $19.91 | ▼ −8.80% | ▼ −7.74% | $20.39 (−6.60%) |
Jul 27, 2026 13w ago | 6-K | $19.27 $20.94 | ▼ −8.67% | ▼ −5.37% | $20.39 (−5.81%) |
Jul 27, 2026 13w ago | Press Release | $19.27 $20.94 | ▲ +8.67% | ▲ +5.37% | $20.39 (+5.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers